Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 16 Jul 2022
Monkeypox patients should not be left to suffer when an FDA approved drug could help
15 July 2022 - Andy couldn’t sleep more than a couple fitful hours a night because it felt like a ...
Posted by Michael Wonder on 15 Jul 2022
UK lags behind EU in authorising new medicines after Brexit
14 July 2022 - Experts attribute shortfall to small size of British market now it is regulated separately and complexity of ...
Posted by Michael Wonder on 15 Jul 2022
PBAC Public Summary Documents (first time rejections and deferrals) – March 2022 meeting
15 July 2022 - The Public Summary Documents (first time rejections and deferrals) from the March 2022 PBAC meeting are now ...
Posted by Michael Wonder on 15 Jul 2022
Health Canada authorises use of Moderna COVID-19 vaccine in children 6 months to 5 years of age
14 July 2022 - Today, Health Canada authorised the use of the Moderna Spikevax COVID-19 vaccine in children 6 months to ...
Posted by Michael Wonder on 15 Jul 2022
TGA approves Grifols' Xembify
15 July 2022 - Xembify is yet another presentation of human immunoglobulin. ...
Posted by Michael Wonder on 15 Jul 2022
Chief Medical Officer’s statement on standard of care on COVID-19 oral antiviral treatments in residential aged care facilities
15 July 2022 - A statement from Professor Paul Kelly, Australian Government Chief Medical Officer, about the standard of care on ...
Posted by Michael Wonder on 14 Jul 2022
Marinus Pharmaceuticals sells rare paediatric disease priority review voucher for $110 million
14 July 2022 - Marinus Pharmaceuticals today announced that it has entered into a definitive agreement to sell its rare ...
Posted by Michael Wonder on 14 Jul 2022
Breakthrough treatment to boost life chances for hundreds of people with respiratory cancer
14 July 2022 - The first new mesothelioma treatment to be approved in nearly 15 years will be made available ...
Posted by Michael Wonder on 14 Jul 2022
FDA clears DyAnsys neurostimulation device first relief to treat diabetic neuropathic pain
14 July 2022 - First Relief, a PENS (percutaneous electrical neurostimulation) device, has been cleared by the US FDA for ...
Posted by Michael Wonder on 14 Jul 2022
Thousands of patients to benefit as NHS marks 100th fast tracked cancer drug
14 July 2022 - Thousands of people a year with advanced breast cancer will benefit from a life extending drug ...
Posted by Michael Wonder on 14 Jul 2022
FDA approves crizotinib for ALK positive inflammatory myofibroblastic tumour
14 July 2022 - On 14 July 2022, the FDA approved crizotinib (Xalkori, Pfizer) for adult and paediatric patients one ...
Posted by Michael Wonder on 14 Jul 2022
COVID-19 vaccine safety report (14 July 2022)
14 July 2022 - To 10 July 2022, the TGA has received 609 reports which have been assessed as likely to ...
Posted by Michael Wonder on 14 Jul 2022
Roxadustat for treating symptomatic anaemia in chronic kidney disease
13 July 2022 - NICE has published evidence-based recommendations on the use of roxadustat (Evrenzo) for the treatment of adults ...
Posted by Michael Wonder on 14 Jul 2022
Revolo Biotherapeutics awarded Innovation Passport for ‘1805 in the United Kingdom for the treatment of moderate to severe rheumatoid arthritis
14 July 2022 - Revolo Biotherapeutics today announced that it was awarded an Innovative Medicines Designation, or Innovation Passport, from the ...
Posted by Michael Wonder on 14 Jul 2022
BeiGene provides regulatory update on the U.S. biologics license application for PD-1 inhibitor tislelizumab in second-line oesophageal squamous cell carcinoma
14 July 2022 - Due to COVID travel restrictions, inspections could not be completed during review period. ...